Full-Time

Head of Clinical Operations

Confirmed live in the last 24 hours

Tessera Therapeutics

Tessera Therapeutics

201-500 employees

Develops gene editing technology for genetic medicine

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Healthcare Administration & Support
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • MS, MBA, MPH or PhD with 15+ years of industry experience, 10+ years of clinical operations line management experience.
  • Excellent understanding and demonstrated application of FDA guidelines, Good Clinical Practice (GCP), ICH and applicable Standard Operating Procedures.
Responsibilities
  • Leading all operational aspects of clinical studies and patient registries to achieve corporate goals for timelines, budget and quality.
  • Selecting and overseeing vendors, including Contract Research Organizations (CROs), laboratory vendors, and other third parties, to ensure they meet timelines, budgets, quality, compliance, and goals.
  • Reaching patient recruitment goals by leading the operational strategy for identifying, recruiting, and retaining trial subjects.
  • Preparing clinical operations plans, timelines/costs/resources, documents/presentations for internal planning and study execution.
  • Leading efforts to identify and build relationships with key investigators and trial sites to ensure successful execution of clinical studies in compliance with GCP/ICH, global regulatory and patient safety requirements.
  • Supporting regulatory submissions including timeline planning, data preparation, document generation, inspection readiness, and query responses.
  • Representing the company as a senior clinical operations spokesperson before appropriate scientific, medical, regulatory, and business associates.

Tessera Therapeutics focuses on genetic medicine, specifically through a technology called Gene Writing, which enables precise modifications to the human genome. This technology allows for permanent changes to genetic material in any cell, aiming to cure diseases at their source. Tessera's Gene Writing can perform both small and large genetic alterations, making it applicable to a wide range of genetic disorders. The company collaborates with research institutions, pharmaceutical companies, and healthcare providers to develop new treatments. Tessera generates revenue through partnerships, licensing agreements, and the potential sale of its technology. With significant funding secured, Tessera aims to advance its platform and fulfill its goal of curing diseases by rewriting genetic code.

Company Stage

Series C

Total Funding

$517.2M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-14%

1 year growth

-13%

2 year growth

13%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tessera's innovative Gene Writing technology has the potential to cure previously untreatable genetic conditions, offering a transformative impact on healthcare.
  • The company's strategic partnerships and licensing agreements with major pharmaceutical firms and research institutions can drive significant revenue growth and market penetration.
  • Recent leadership appointments, including a new General Counsel and Chief Regulatory Officer, bring extensive industry experience that can guide the company through regulatory and commercial milestones.

What critics are saying

  • The highly competitive biotechnology sector requires continuous innovation to maintain Tessera's market position.
  • Regulatory hurdles and the complexity of clinical trials for genetic therapies could delay product development and commercialization.

What makes Tessera Therapeutics unique

  • Tessera Therapeutics' Gene Writing technology offers a unique capability to make precise and permanent genetic alterations, setting it apart from traditional gene editing methods.
  • The company's focus on a wide range of genetic disorders, from phenylketonuria to sickle cell disease, showcases the versatility and broad applicability of its platform.
  • Securing $300 million in Series C financing highlights strong investor confidence and provides substantial resources for advancing their groundbreaking technology.

Help us improve and share your feedback! Did you find this helpful?